

NEWS RELEASE



CONTACT: Joan Schimml
Senior Director, Corporate Communications and Events
(952) 833-6582

(For immediate release)

i3 ACQUIRES EUROPE'S PRESTIGIOUS RESEARCH FIRM, EUROPEAN HEALTH ECONOMICS

*i3 Innovus Assembling Elite Global Team to Deliver the Science and Solutions to
Achieve Marketplace Success for Biopharmaceutical Products*

*EHE Brings Specialized Expertise and Sophisticated Research to Economic
Evaluation of Health Interventions and Technologies*

MEDFORD, Mass., May 6, 2007—Pharmaceutical services company i3, a global Ingenix business, has acquired European Health Economics (EHE), one of Europe's most prestigious health economics research firms. EHE will join the i3 Innovus business unit which provides health economics expertise, rich data and sophisticated econometric research to the biopharmaceutical industry. This acquisition contributes to i3's continuing strategic global expansion and brings EHE's leading health economic experts and methodologies to solidify i3 Innovus' position as a premier global health economics and outcomes research organization.

With world-renowned experts and industry-leading databases, i3 Innovus delivers the real-world proof its clients need to demonstrate the value of new pharmaceutical products and medical technologies, to help those products succeed in the market, and ultimately to improve more patients' lives. With offices in Sweden and the UK, EHE is known for its high-quality health economics and modeling and will now have complete access to i3 Innovus' uniquely rich database and smart software applications. EHE further strengthens i3 Innovus in delivering timely, meaningful information to support every aspect of product decision-making.

Dr. William Crown, Ph.D., president of i3 Innovus, said, "i3's strategy is to bring together the best minds in health economics and outcomes with access to the best informatics and richest databases available. With the addition of EHE, we have expanded our elite team of world-renowned methodological leaders in health care economics in the European market, whose insight and unique expertise will greatly benefit our clients."

-more-

EHE ACQUISITION/2

Dr. Linus Jönsson, M.D., MSc, Ph.D., chief executive officer of EHE, said, “For EHE, there are enormous advantages in joining an organization with the global reach and breadth of services i3 Innovus has to offer. Linking to i3’s global clinical research capabilities will be especially advantageous for our European clients interested in the burgeoning U.S. market for biopharmaceutical products.”

i3 has brought together some of the world’s leading minds in the health economics field. Led by William Crown, Ph.D., i3 Innovus now includes among its principal consultants:

- Bengt Jönsson, Ph.D., director of the Stockholm School of Economics, Center for Health Economics
- Michael Drummond, professor of Health Economics, former director of the Centre for Health Economics (University of York) and current president of the International Society for Pharmacoeconomics and Outcomes Research
- Milton Weinstein, Ph.D., Henry J. Kaiser professor at the Harvard School of Public Health and the Harvard Medical School, and director of the Program on Economic Evaluation of Medical Technology in the Department of Health Policy and Management
- George Torrance, Ph.D., professor emeritus of Clinical Epidemiology and Biostatistics at McMaster University and a pioneer in the methods of economic evaluation of health care
- Alistair McGuire, Ph.D., professor of Health Economics at London School of Economics Health and Social Care
- Stuart MacLeod, M.D., Ph.D., FRCPC, executive director of British Columbia’s Child & Family Research Institute, vice president of the BC Provincial Health Services Authority, and assistant dean and professor, Faculty of Medicine, University of British Columbia

About i3

i3, a global Ingenix company, provides integrated scientific strategies and solutions throughout the pharmaceutical product lifecycle. It is composed of i3 Research, a therapeutically specialized contract research organization; i3 Drug Safety, engaged in pharmacovigilance and epidemiology; i3 Statprobe, a leader in comprehensive data services; i3 Pharma Resourcing, a world-class staffing partner; i3 Innovus, delivering the science and solutions to achieve marketplace success; and i3 CME, providing certified medical education. i3 helps companies gain sharper insights that lead to better patient care. For more information, visit www.i3global.com.

###